Androgenetic Alopecia Epidemiology Forecast 2023 -2032 - ResearchAndMarkets.com

The "Androgenetic Alopecia - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

This 'Androgenetic Alopecia - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of androgenetic alopecia in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom and Japan.

Androgenetic Alopecia: Disease Understanding

Androgenetic Alopecia Overview

Androgenetic alopecia is a genetically predetermined disorder due to an excessive response to androgens. This condition affects up to 50% of males and females and is characterized by progressive loss of terminal hair of the scalp any time after puberty. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women, the frontal hairline is typically spared with diffuse hair loss at the crown and top of the head, with loss often marked by a wider center part.

Androgenetic alopecia is usually diagnosed clinically with a history of gradual onset after puberty and, often but not necessarily, a family history of baldness. A biopsy is usually not necessary unless the diagnosis is unclear. Dermoscopy shows miniaturized hair and brown perihilar casts, which can help differentiate from diffuse alopecia areata that mimics male pattern baldness as diffuse alopecia areata will have tapered fractures such as exclamation point hairs.

Topical minoxidil (ROGAINE) and finasteride (PROPECIA) are the two drugs approved by the US Food and Drug Administration (FDA) for androgenetic alopecia, both of which require at least a 4-6 month trial before noticing improvement and must be used indefinitely to maintain a response.

Other off-label therapies used for androgenetic alopecia management include spironolactone, dutasteride, prostaglandin analogs, laser treatments, cyproterone acetate, platelet-rich plasma, and more. Besides drug therapies, hair transplantation is also a preferred surgical approach in androgenetic alopecia treatment. Various emerging drugs in development promise better hair loss control and promote hair regrowth.

Epidemiology

The androgenetic alopecia epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted androgenetic alopecia epidemiology segmented as the total prevalent cases of androgenetic alopecia, total prevalent cases of androgenetic alopecia in males, total prevalent cases of androgenetic alopecia in females, total diagnosed prevalent cases of androgenetic alopecia in males and total diagnosed prevalent cases of androgenetic alopecia in females. The report includes the total prevalent cases of androgenetic alopecia in the 7MM covering the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan from 2019 to 2032.

Country-wise Androgenetic Alopecia Epidemiology

The epidemiology segment also provides the androgenetic alopecia epidemiology data and findings across the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.

The total prevalent cases of androgenetic alopecia were more than 194,000,000 in the 7MM in 2021.

As per the estimates, EU4 and the UK had the highest prevalent patient population of androgenetic alopecia in 2021. Among EU4 and the UK, Germany had the highest number of cases of androgenetic alopecia, with more than 22,000,000 cases, followed by the UK in 2021. On the other hand, Spain had the lowest number of cases of androgenetic alopecia, with nearly 12,000,000 cases in 2021.

Scope of the Report

• The androgenetic alopecia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Androgenetic alopecia epidemiology report and model provide an overview of the risk factors and global trends of Parkinson's disease levodopa-induced dyskinesia in the seven major markets (7MM: The US, France, Germany, Italy, Spain, the UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of androgenetic alopecia in seven major markets covering the United States, EU4 and the UK, and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of androgenetic alopecia.
• The report describes Androgenetic Alopecia epidemiology by the number of patients developing androgenetic alopecia in the 7MM.
• The report describes the androgenetic alopecia epidemiology by the type-specific cases of androgenetic alopecia patients in the 7MM.

Report Highlights

• 11-year Forecast of Androgenetic Alopecia Epidemiology
• 7MM Coverage
• Number of patients developing Androgenetic Alopecia
• Type-specific cases of Androgenetic Alopecia

KOL Views

The publisher interviews KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, and this will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in an indication of androgenetic alopecia during the forecast period (2019-2032)?
• What key findings about androgenetic alopecia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with androgenetic alopecia across the 7MM forecast period (2019-2032)?
• Among the EU4 and the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of androgenetic alopecia?
• What currently available treatments for androgenetic alopecia?

Reasons to Buy

Androgenetic alopecia epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global androgenetic alopecia market.
• Quantify patient populations in the global androgenetic alopecia market to improve product design, pricing, and launch plans.
• Understand the magnitude of the androgenetic alopecia population by the number of patients developing androgenetic alopecia.
• Understand the magnitude of the androgenetic alopecia population by its type-specific cases.
• The androgenetic alopecia epidemiology report and model were written and developed by Master and PhD epidemiologists'.
• The androgenetic alopecia epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 and the United Kingdom
• Japan

Study Period: 2019-2032

For more information about this report visit https://www.researchandmarkets.com/r/vsygrz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005683/en/